PharmacoEconomics and Outcomes News

EU wants India to accept "data exclusivity" proposal for generics
pp. 1-1(1)

GP commissioners "face formidable obstacles"
pp. 2-2(1)

Doctors say reform will change NHS, but not in a good way
pp. 2-2(1)

NCCN updates breast and prostate cancer, CML and NHL guidelines
pp. 3-3(1)

Australian health reform plans released
pp. 3-3(1)

More opposition to the NHS reforms
pp. 4-4(1)

Goal-directed therapy beneficial in sepsis
pp. 4-4(1)

Hopes for fewer deaths, lower costs with genetic guided dosing
pp. 4-4(1)

Bevacizumab costly for ovarian cancer
pp. 5-5(1)

Additional integrated HIV care costs revealed
pp. 5-5(1)

Bivalent HPV vaccine outshines quadrivalent vaccine?
pp. 5-5(1)

QOL news from AAD
pp. 6-6(1)

NICE result from venous thromboembolism screening
pp. 7-7(1)

Capsaicin patch of benefit in postherpetic neuralgia
pp. 7-7(1)

Combined therapy for SSRI-resistant depression?
pp. 7-7(1)

Medical education leads to gains in COPD management
pp. 7-7(1)

Would you pay more for branded drugs?
pp. 8-8(1)

US researchers dismiss contention against generics
pp. 8-8(1)

Pre-emptive genotyping leads to a reduction in toxicity and costs
pp. 8-8(1)

Botulinum toxin A boosts QOL in MS
pp. 8-8(1)

Physicians and MCOs don't always see eye to eye
pp. 9-9(1)

NICE rejects three cancer treatments
pp. 9-9(1)

Access to Xeomin expanded in the USA . . .
pp. 10-10(1)

SMC approves six drugs
pp. 10-10(1)

Ranibizumab not recommended for DMO by NICE
pp. 10-10(1)

Victoza likely to make Bydureon's market entry difficult
pp. 11-11(1)

New listings on the Australian PBS and NIP
pp. 11-11(1)

NICE consults on draft guidance for test to rule out MI
pp. 11-11(1)